8-K

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



         Date of Report (Date of earliest event reported): March 9, 2004


                              DELCATH SYSTEMS, INC.
             (Exact name of registrant as specified in its charter)

      Delaware                     001-16133                  06-1245881
   (State or other          (Commission File Number)        (IRS Employer
    jurisdiction of                                        Identification No.)
    incorporation)


                 1100 Summer Street, Stamford, Connecticut 06905
              (Address of principal executive offices and zip code)


       Registrant's telephone number, including area code: (203) 323-8668


                                       N/A
          (Former name or former address, if changes since last report)







                                                                               2




Item 5. Other Events and Regulation FD Disclosure

     On March 9, 2004, Delicate Systems, Inc. (the "Company") issued a press
release relating to the enrollment of the first patient in its Phase III
clinical trial for inoperable cancer in the liver Company's press release dated
March 9, 2004 is incorporated herein by reference and filed as an exhibit
hereto.

Item 7. Financial Statements and Exhibits.

     (a) Not applicable

     (b) Not applicable.

     (c) Exhibits:

        Exhibit                     Description
        -------                     -----------

          99      Press Release dated March 9, 2004 of Delcath Systems, Inc.






                                                                              3




                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    DELCATH SYSTEMS, INC.

                                    By:  /s/ M. S. KOLY
                                       ----------------------
                                       M. S. Koly
                                       President and Chief Executive Officer


Date: March 9, 2004







                                   EXHIBIT INDEX


        Exhibit                     Description
        -------                     -----------

          99      Press Release dated March 9, 2004 of Delcath Systems, Inc.

EX-99

Release Date: Immediate





Contact:
        M.S. Koly                       Thomas Redington
        Chief Executive Officer         Redington, Inc.
        Delcath Systems, Inc.           203/222-7399
        203/323-8668                    212/926-1733
        www.delcath.com                 www.redingtoninc.com


         FIRST PATIENT ACCEPTED IN DELCATH PHASE III LIVER CANCER STUDY

     STAMFORD, CT MAR. 9 - Delcath Systems, Inc. (Nasdaq: DCTH) said the first
patient has been accepted for enrollment in its Phase III clinical trial for
inoperable cancer in the liver.

     The patient will be treated at the Sydney Melanoma Unit at the Royal Price
Alfred Hospital in Sydney, Australia, the initial clinical site for the
company's pivotal trial.

     "This is an important milestone for our company and marks the beginning of
our final step toward FDA approval," said M.S. Koly, CEO of Delcath. "Now that
the first patient is enrolled, the clinical team in Sydney indicated to us that
future enrollments should happen at a more rapid pace."

     Delcath is undertaking the Phase III pivotal trial for FDA approval to
commercialize its isolated liver perfusion system for delivery of high dose
chemotherapy directly to the liver via the hepatic artery. The FDA-approved
protocol calls for enrolling 122 patients (including 61 controls) to determine
whether patients treated with Delcath's system experience statistically longer
survival versus the control group.

     The Delcath system uses special catheters and filters to direct and trap
toxic anticancer chemicals, so they can be delivered in high doses to the liver
while protecting the rest of the body from excessive toxicity.

     The Phase III study is testing the drug doxorubicin in patients with
melanoma metastasized to the liver.

     Omnicare, Inc. (NYSE: OCR), a global contract research organization with 29
principal offices and a presence in 27 countries, is managing the trial on
behalf of Delcath.

     The principal investigator of the Sydney study is John Thompson, MD,
Director of the Sydney Melanoma Unit at the Royal Price Alfred Hospital and
professor of surgery (melanoma and surgical oncology) at the University of
Sydney. He is a world leader in the development of perfusion and infusion
therapies for regional treatment of recurrent melanoma.

     The Sydney Melanoma Unit has accumulated the largest database of melanoma
patients in the world. It has treated more than 15,000


                                     -more-





melanoma patients since its inception in 1968 and sees approximately 750 new
melanoma patients yearly.

     Delcath is a developer of isolated perfusion technology for organ or
region-specific delivery of therapeutic agents. Six US, and three foreign issued
patents cover its technology. The company is headquartered in Stamford, CT.

                                      # # #

     This release contains "forward-looking statements" based on current
expectations but involving known and unknown risks and uncertainties. Actual
results or achievements may be materially different from those expressed or
implied. Delcath plans and objectives are based on assumptions involving
judgments with respect to future economic, competitive and market conditions,
its ability to consummate, and the timing of, acquisitions and future business
decisions, all of which are difficult or impossible to predict accurately and
many of which are beyond its control. Therefore, there can be no assurance than
any forward-looking statement will prove to be accurate.